BackConduit Pharmaceuticals- Warrants (22/09/2028) Overview

Conduit Pharmaceuticals- Warrants (22/09/2028) Total Current Liabilities

Conduit Pharmaceuticals- Warrants (22/09/2028)'s total current liabilities is $650M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$652.79M
↑ 6.04% YoYΔ $37.19M vs prior year quarter

Peer trimmed avg / median

Loading

Conduit Pharmaceuticals- Warrants (22/09/2028) Total Current Liabilities History

Loading

Conduit Pharmaceuticals- Warrants (22/09/2028) vs. peers: Total Current Liabilities Comparison

Loading

Conduit Pharmaceuticals- Warrants (22/09/2028) Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Conduit Pharmaceuticals- Warrants (22/09/2028) (CDTTW) FAQ

The latest total current liabilities for CDTTW is $650M as of June 2026. That compares with $620M in the prior-year period — up 6.0% year over year. Investors often review this figure alongside Conduit Pharmaceuticals- Warrants (22/09/2028)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, CDTTW's total current liabilities moved from $620M to $650M — a 6.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Conduit Pharmaceuticals- Warrants (22/09/2028)'s operating scale or balance-sheet position.

A total current liabilities figure of $650M for CDTTW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CDTTW's total current liabilities ($650M), review year-over-year change from $620M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.